Head-To-Head Contrast: Evoke Pharma (EVOK) versus The Competition
Evoke Pharma (NASDAQ: EVOK) is one of 116 publicly-traded companies in the “Pharmaceuticals” industry, but how does it compare to its peers? We will compare Evoke Pharma to similar businesses based on the strength of its profitability, valuation, earnings, risk, dividends, analyst recommendations and institutional ownership.
Earnings & Valuation
This table compares Evoke Pharma and its peers top-line revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Evoke Pharma Competitors||$8.20 billion||$2.68 billion||-1.59|
Evoke Pharma’s peers have higher revenue and earnings than Evoke Pharma. Evoke Pharma is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
This table compares Evoke Pharma and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Evoke Pharma Competitors||-2,859.71%||-67.96%||-9.24%|
This is a summary of current ratings for Evoke Pharma and its peers, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Evoke Pharma Competitors||840||3776||6801||185||2.55|
Evoke Pharma currently has a consensus target price of $8.86, indicating a potential upside of 202.29%. As a group, “Pharmaceuticals” companies have a potential upside of 24.76%. Given Evoke Pharma’s stronger consensus rating and higher probable upside, research analysts clearly believe Evoke Pharma is more favorable than its peers.
Institutional and Insider Ownership
12.9% of Evoke Pharma shares are held by institutional investors. Comparatively, 44.3% of shares of all “Pharmaceuticals” companies are held by institutional investors. 20.0% of Evoke Pharma shares are held by insiders. Comparatively, 12.0% of shares of all “Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Volatility & Risk
Evoke Pharma has a beta of 1.19, meaning that its share price is 19% more volatile than the S&P 500. Comparatively, Evoke Pharma’s peers have a beta of 0.89, meaning that their average share price is 11% less volatile than the S&P 500.
Evoke Pharma beats its peers on 6 of the 11 factors compared.
Evoke Pharma Company Profile
Evoke Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. EVK-001 is a formulation of Metoclopramide drug, designed to provide systemic delivery of metoclopramide through intranasal administration. The Company has evaluated EVK-001 in a multicenter, randomized, double-blind, placebo-controlled parallel group, dose-ranging Phase IIb clinical trial. The Company has commenced a Phase III clinical trial of EVK-001 in female patients with symptoms associated with acute and recurrent diabetic gastroparesis. The Phase III clinical trial is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study evaluating the efficacy, safety and population pharmacokinetics of EVK-001 in adult females.
Receive News & Ratings for Evoke Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.